CSIMarket
 


Moderna Inc   (MRNA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

MRNA's Income from Cont. Operations Growth by Quarter and Year

Moderna Inc 's Income from Cont. Operations results by quarter and year




MRNA Income from Cont. Operations (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - -272.49 -4.08 7.78
III Quarter September - -233.64 -2.56 -7.78
II Quarter June 2,780.00 -116.71 -2.78 -4.65
I Quarter March 1,221.00 -124.23 -2.56 -1.36
FY   4,001.00 -747.07 -11.98 -6.01



MRNA Income from Cont. Operations second quarter 2021 Y/Y Growth Comment
Moderna Inc in the second quarter achieved Income from Cont. Operations of $ 2,780.00 millions compare to loss from continued operations recorded in same quarter a year ago.

Among companies who have reported second quarter results in the Biotechnology & Drugs industry only one Company has achieved higher year on year Income from Cont. Operations results in the second quarter. While Moderna Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. 40 in the second quarter.




MRNA Income from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Moderna Inc 's second quarter 2021 Income from Cont. Operations $ 2,780.00 millions MRNA's Income Statement
Moderna Inc 's second quarter 2020 Income from Cont. Operations $ -116.71 millions Quarterly MRNA's Income Statement
New: More MRNA's historic Income from Cont. Operations Growth >>


MRNA Income from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June 127.68 % - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #5
Overall #40

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
484.27 % 484.27 % 484.27 %
(Jun 30 2021)  
Income from Cont. Operations second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #5
Overall #40
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
484.27 % 484.27 % 484.27 %
(Jun 30 2021)  

Income from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Moderna Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
127.68 % 34.2 % -89.24 %
(Jun 30 2021)  


MRNA's II. Quarter Q/Q Income from Cont. Operations Comment
Moderna Inc achieved in the II. Quarter 2021 above company average sequential Income from Cont. Operations doubling of 127.68%, to $ 2,780.00 millions, from $1,221.00 millions in the first quarter.
MRNA is impressively improving, not just reporting better then regular gain, but also increasing speed.

Within Biotechnology & Drugs industry 2 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Moderna Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 249.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #3
Healthcare Sector #20
Overall #249
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #3
Healthcare Sector #20
Overall #249
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
127.68 % 34.2 % -89.24 %
(Jun 30 2021)  


MRNA's II. Quarter Q/Q Income from Cont. Operations Comment
Moderna Inc achieved in the II. Quarter 2021 above company average sequential Income from Cont. Operations doubling of 127.68%, to $ 2,780.00 millions, from $1,221.00 millions in the first quarter.
Moderna Inc is impressively improving, with recording above average increase, and additionally increasing pace, Caitlin  D. Clarke, an industry researcher located in Liverpool added.

Within Biotechnology & Drugs industry 2 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Moderna Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 249.


Moderna Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
Cumulative Income from Cont. Operations 12 Months Ending $ 3,494.88 $ 598.17 $ -747.06 $ -478.66 $ -247.58
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) 484.27 % - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 40 # 0 # 0 # 0 # 0




Cumulative Income from Cont. Operations growth Comment
In the Jun 30 2021 period, Moderna Inc had cumulative twelve months Income from Cont. Operations of $ 3,495 millions compare to loss from continued operations of $ -248 millions a year ago.

Moderna Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
484.27 %
484.27 %
484.27 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 5
S&P 500 # 40
Cumulative Income from Cont. Operations growth Comment
In the Jun 30 2021 period, Moderna Inc had cumulative twelve months Income from Cont. Operations of $ 3,495 millions compare to loss from continued operations of $ -248 millions a year ago.

Moderna Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
484.27 %
484.27 %
484.27 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 5
S&P 500 # 40




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
MRNA's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for MRNA's Competitors
Income from Cont. Operations Growth for Moderna Inc 's Suppliers
Income from Cont. Operations Growth for MRNA's Customers

You may also want to know
MRNA's Annual Growth Rates MRNA's Profitability Ratios MRNA's Asset Turnover Ratio MRNA's Dividend Growth
MRNA's Roe MRNA's Valuation Ratios MRNA's Financial Strength Ratios MRNA's Dividend Payout Ratio
MRNA's Roa MRNA's Inventory Turnover Ratio MRNA's Growth Rates MRNA's Dividend Comparisons



Companies with similar Income from Cont. Operations doubling for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jun 30 2021
Eli Lilly And Company-1.54%$ -1.544 millions
Bio rad Laboratories Inc -5.41%$ -5.413 millions
Corcept Therapeutics Inc-6.37%$ -6.368 millions
Zynex Inc-6.93%$ -6.927 millions
Pacific Health Care Organization Inc-11.14%$ -11.144 millions
Lhc Group Inc-19.11%$ -19.114 millions
Tenax Therapeutics Inc-20.01%$ -20.010 millions
Recro Pharma Inc -22.10%$ -22.096 millions
Apollo Medical Holdings Inc -26.51%$ -26.507 millions
Reynolds Consumer Products Inc -28.57%$ -28.571 millions
Msa Safety Inc-30.27%$ -30.267 millions
Chemed Corporation-31.16%$ -31.156 millions
Supernus Pharmaceuticals inc -31.56%$ -31.560 millions
Co diagnostics Inc -34.79%$ -34.787 millions
Biogen Inc -36.17%$ -36.166 millions
Petmed Express Inc-43.00%$ -42.997 millions
The Pennant Group Inc -43.07%$ -43.071 millions
Neurocrine Biosciences Inc -46.86%$ -46.859 millions
Hill rom Holdings Inc -47.60%$ -47.604 millions
Incyte Corp-48.52%$ -48.516 millions
Molecular Templates Inc -50.04%$ -50.042 millions
Meridian Bioscience Inc -57.58%$ -57.578 millions
Healthcare Services Group Inc -58.59%$ -58.595 millions
Merck and Co Inc -59.67%$ -59.668 millions
Community Health Systems Inc -60.22%$ -60.215 millions
Pro Dex Inc-66.50%$ -66.496 millions
Hanger inc -67.29%$ -67.286 millions
Tivity Health Inc -69.24%$ -69.236 millions
Electromed Inc -69.47%$ -69.467 millions
Quidel Corporation-71.81%$ -71.807 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MTRX's Profile

Stock Price

MTRX's Financials

Business Description

Fundamentals

Charts & Quotes

MTRX's News

Suppliers

MTRX's Competitors

Customers & Markets

Economic Indicators

MTRX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071